CN115400065A - Skin care composition with multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing and application thereof - Google Patents
Skin care composition with multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing and application thereof Download PDFInfo
- Publication number
- CN115400065A CN115400065A CN202211003459.8A CN202211003459A CN115400065A CN 115400065 A CN115400065 A CN 115400065A CN 202211003459 A CN202211003459 A CN 202211003459A CN 115400065 A CN115400065 A CN 115400065A
- Authority
- CN
- China
- Prior art keywords
- skin care
- skin
- care composition
- extract
- ceramide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- 230000000694 effects Effects 0.000 title claims abstract description 47
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 22
- 230000037303 wrinkles Effects 0.000 title abstract description 44
- 230000032683 aging Effects 0.000 title abstract description 20
- -1 glycerol glucoside Chemical class 0.000 claims abstract description 77
- 239000000284 extract Substances 0.000 claims abstract description 75
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 73
- 108010035532 Collagen Proteins 0.000 claims abstract description 42
- 102000008186 Collagen Human genes 0.000 claims abstract description 42
- 229920001436 collagen Polymers 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 30
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 29
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 29
- 229960000367 inositol Drugs 0.000 claims abstract description 29
- 240000005924 Stenocarpus sinuatus Species 0.000 claims abstract description 26
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 25
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 25
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 25
- 235000020638 mussel Nutrition 0.000 claims abstract description 25
- 229930182478 glucoside Natural products 0.000 claims abstract description 23
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 20
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 20
- 229940106189 ceramide Drugs 0.000 claims abstract description 20
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 20
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 16
- 108010031318 Vitronectin Proteins 0.000 claims abstract description 14
- 102100035140 Vitronectin Human genes 0.000 claims abstract description 14
- 239000006071 cream Substances 0.000 claims abstract description 12
- 241000125183 Crithmum maritimum Species 0.000 claims abstract description 6
- 229940072117 fennel extract Drugs 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims abstract description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 235000019766 L-Lysine Nutrition 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 17
- 229930064664 L-arginine Natural products 0.000 claims description 17
- 235000014852 L-arginine Nutrition 0.000 claims description 17
- 239000004472 Lysine Substances 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 17
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 15
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 15
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 14
- 230000003712 anti-aging effect Effects 0.000 claims description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 14
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 13
- 240000007817 Olea europaea Species 0.000 claims description 13
- 229940057910 shea butter Drugs 0.000 claims description 13
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 12
- 229940049964 oleate Drugs 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 11
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 11
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 11
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 10
- 235000013871 bee wax Nutrition 0.000 claims description 10
- 239000012166 beeswax Substances 0.000 claims description 10
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 10
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 10
- 235000010384 tocopherol Nutrition 0.000 claims description 10
- 239000011732 tocopherol Substances 0.000 claims description 10
- 229960001295 tocopherol Drugs 0.000 claims description 10
- 229930003799 tocopherol Natural products 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 10
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 7
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 claims description 5
- 241001534815 Hypsizygus marmoreus Species 0.000 claims description 5
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 5
- 229940092738 beeswax Drugs 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003998 snake venom Substances 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- 108010087806 Carnosine Proteins 0.000 claims description 3
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 claims description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 3
- GCDXVKZXCQGDHC-BLCQCPAESA-N [30-oxo-30-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]triacontyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C\C=C/CCCCC GCDXVKZXCQGDHC-BLCQCPAESA-N 0.000 claims description 3
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 3
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 3
- 229940044199 carnosine Drugs 0.000 claims description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 3
- 229940086668 ceramide eop Drugs 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- XOICCXUBQCQYKD-UHFFFAOYSA-N [Na].[Na].C(CCC)(O)O Chemical compound [Na].[Na].C(CCC)(O)O XOICCXUBQCQYKD-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940047670 sodium acrylate Drugs 0.000 claims 1
- 230000001815 facial effect Effects 0.000 abstract description 16
- 239000002537 cosmetic Substances 0.000 abstract description 12
- 239000000686 essence Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 232
- 238000012360 testing method Methods 0.000 description 66
- 230000000052 comparative effect Effects 0.000 description 44
- 239000000047 product Substances 0.000 description 27
- 230000008439 repair process Effects 0.000 description 24
- 230000037394 skin elasticity Effects 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- 230000008859 change Effects 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 241000252212 Danio rerio Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 7
- 150000003278 haem Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241001537183 Hypecoum Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108030001720 Bontoxilysin Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000037067 skin hydration Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 239000005740 Boscalid Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 241000720991 Illicium Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 240000004760 Pimpinella anisum Species 0.000 description 2
- 235000012550 Pimpinella anisum Nutrition 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940118790 boscalid Drugs 0.000 description 2
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- DDADCBXAKYGDEH-UHFFFAOYSA-N 2-(3-hydroxypropyl)oxane-2,3,4-triol Chemical compound OCCCC1(O)OCCC(O)C1O DDADCBXAKYGDEH-UHFFFAOYSA-N 0.000 description 1
- DCRRVDXYSHOJEF-UHFFFAOYSA-N 4-amino-N-benzylbutanamide Chemical compound NCCCC(=O)NCC1=CC=CC=C1 DCRRVDXYSHOJEF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241000201895 Salicornia Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 241000722921 Tulipa gesneriana Species 0.000 description 1
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 description 1
- 101710109022 UBX domain-containing protein 4 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- VEFKIGFJSFFFIE-UHFFFAOYSA-M sodium (4-hydroxyphenyl)methanesulfonate Chemical compound [Na+].OC1=CC=C(CS([O-])(=O)=O)C=C1 VEFKIGFJSFFFIE-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000009891 weiqi Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- 150000003741 xylose derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
The application relates to the technical field of cosmetics, and provides a skin care composition with multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing and application thereof. The skin care composition comprises, based on the total weight of the skin care composition: 1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 0.1-8wt% of peptide, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of sea fennel extract, 0.1-8wt% of tulip flower extract and 0.1-8wt% of mussel extract, and the balance of water. According to the skin care product composition provided by the application, the obtained skin care product composition has various effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing through scientific proportioning of multiple components, can provide comprehensive care for skin, and enables the skin to keep healthy, glossy and beautiful; the skin care composition can be applied to various skin care products such as cream, lotion, essence, moisturizing water, facial mask and the like.
Description
Technical Field
The application relates to the technical field of cosmetics, in particular to a skin care composition with multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing and application thereof in cosmetics.
Background
With the general rising trend of the absolute value of the retail total of consumer goods in China, the consumption potential is released continuously. People have higher and higher requirements on beauty, and besides the daily used moisture retention, products with various effects are full of precious stones. Meanwhile, the market education of skin management is deepened, the requirements of residents on the living quality are improved, the consumption demand of boosting cosmetics is increased, and the total retail amount of the cosmetics in China is also gradually increased year by year.
In 2022, the cosmetic industry has just entered the efficacy era, and the concurrent upgrade of efficacy is the pursuit of consumers for effective ingredients. In the day ahead, a huge engine mass consumption business center, a huge arithmetic, an arithmetic electronic commerce research institute and Yipusuo Ipsos jointly issue a 2022 Makeup component trend insight report, multi-dimensional data such as jitter content, electronic commerce data and Yipusoo Ipsos whole-network society media number are synthesized, a Makeup component heat and potential component prediction model is constructed, and a Makeup component list TOP50 is issued. From the aspect of component efficacy, the anti-aging and whitening are still the key points of market attention. The entrance list shows that the anti-aging ingredients account for 48 percent of TOP50 heat list. Meanwhile, with the improvement of the consciousness of the consumers on skin care, the components with medical beauty and strong efficacy become a sought-after 'beauty-changing' method, and then the skin repair requirement is brought, and the repair components are relaxed, so that the market opportunity is met.
The cosmetics pay more and more attention to the scientific formula of the product, and the product effect maximization is realized through the collocation of different components. At present, various functional products are available in the market, but most products have single or two functions, and the development of a multi-function product which has the functions of moisturizing, anti-wrinkle and anti-aging and has the functions of relieving and repairing is urgently needed.
Disclosure of Invention
The skin care product composition obtained through scientific proportioning of multiple components has multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing, can provide comprehensive care for skin, and enables the skin to be kept in a young, healthy, glossy and beautiful state.
The present application provides in a first aspect a skin care composition, wherein the skin care composition comprises, based on the total weight of the skin care composition: 1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 0.1-8wt% of peptide, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of sea fennel extract, 0.1-8wt% of tulip flower extract and 0.1-8wt% of mussel extract, and the balance of water.
In some embodiments of the present application, the peptide is selected from at least one of acetyl hexapeptide-8, snake venom peptide, L-arginine/L-lysine polypeptide, and carnosine.
In some embodiments of the present application, the ceramide is selected from at least one of ceramide EOP, ceramide NP, ceramide AS, and ceramide AP.
In some embodiments of the present application, the skin care composition further comprises at least one of cetearyl/sorbitan olivetoleate, cetearyl alcohol, beeswax, isononyl isononanoate, shea butter, dimethicone, tocopherol palmitate, sodium hyaluronate, glycerol, butylene glycol, disodium EDTA, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, p-hydroxyacetophenone, 1, 2-hexanediol, and a fragrance.
In some embodiments of the present application, the skin care composition comprises, based on the total weight of the skin care composition: 1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 0.1-8wt% of peptides, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of hypsizygus marmoreus extract, 0.1-8wt% of tulip flower extract, 0.1-8wt% of mussel extract, 1-5wt% of cetearyl olive oleate/sorbitan olive oleate, 0.1-5wt% of cetearyl alcohol, 0.1-4wt% of beeswax, 2-10wt% of isononyl isononanoate, 0.5-5wt% of shea butter, 0.1-5wt% of polydimethylsiloxane, 0.1-3wt% of tocopherol palmitate, 0.01-0.3wt% of sodium hyaluronate, 2-15wt% of glycerol, 2-10wt% of butanediol disodium EDTA, 0.01-0.3wt% of 0.1-0.1 wt% of hydroxyethyl acrylate, 0.1-5wt% of dimethyl ethyl acrylate, 0.05-1-5 wt% of sodium p-2, and the balance of sodium p-2,.
In a second aspect, the present application provides the use of a skin care composition according to the first aspect of the present application in the preparation of a skin care product.
In some embodiments of the present application, the skin care product has moisturizing, anti-wrinkle, anti-aging, soothing, and repairing effects.
In a third aspect, the present application provides a skin care product comprising a skin care composition according to the first aspect of the present application.
In some embodiments of the present application, the skin care composition is present in the skin care product at a mass fraction of 5% to 20%.
In some embodiments of the present application, the skin care product is selected from one of cream, lotion, essence, moisturizing water, mask, and the like.
The application has the beneficial effects that:
1) According to the skin care product composition provided by the application, the vitronectin, the glycerol glucoside and the inositol are compounded to play a synergistic role, so that the skin hydration effect can be obviously enhanced, the skin elasticity and softness are improved, the skin repairing capability is improved, the skin aging is delayed, and the effects of enhancing moisture retention, resisting wrinkles and resisting aging are achieved;
2) According to the skin care product composition provided by the application, the soluble collagen, the ceramide and the tulip flower extract are compounded to play a synergistic effect, so that the generation of collagen can be remarkably promoted, the water retention of skin is enhanced, the elasticity of the skin is enhanced, and the barrier of the skin is enhanced; the ceramide can form a skin barrier on the skin epidermis, effectively protect the skin from being damaged, effectively prevent the skin from being damaged by the outside, repair the skin, strengthen the wrinkle resistance and the aging resistance, and improve the anti-inflammatory and soothing repairability of the skin;
3) According to the skin care product composition, beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine and L-arginine/L-lysine polypeptide are compounded to play a synergistic effect, cell membranes are formed on epidermal keratin through different action mechanisms, the cell activity is improved, the activity of elastase is improved, the skin elasticity is enhanced, the anti-aging property of the skin is enhanced, the activity of collagen I is promoted, the generation of dermal collagen is promoted, wrinkles of the skin are reduced, the skin is repaired, the wrinkles are removed immediately, the eye lines, the stature lines and the like of the skin are effectively improved, and the skin is kept in a young, glossy and bright healthy state;
4) According to the skin care product composition provided by the application, the ergothioneine and the tulip flower extract are compounded to play a synergistic effect, so that the effects of resisting oxidation and removing free radicals can be improved, and the skin aging can be effectively delayed;
5) According to the skin care product composition provided by the application, the hypsizygus marmoreus extract and the mussel extract are compounded to play a synergistic effect, so that the effects of relieving and repairing skin are enhanced;
6) According to the skin care product composition provided by the application, through the scientific proportioning of multiple components and the synergistic effect, the obtained skin care product composition has multiple effects of moisturizing, resisting wrinkles and aging, relieving and repairing, can provide comprehensive care for skin, and enables the skin to keep a healthy, glossy and beautiful state; the skin care composition can be applied to various skin care products such as cream, lotion, essence, moisturizing water, facial mask and the like.
Of course, not all advantages described above need to be achieved at the same time in the practice of any one product or method of the present application.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings needed to be used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present application, and it is also obvious for a person skilled in the art to obtain other embodiments according to the drawings.
FIG. 1 is a graph comparing the change of a white control group and a test group after the fish tail is repaired for 14 days in a zebra fish repairing efficacy test;
FIG. 2 is a graph comparing the change in eye wrinkles before and after 28 days of use of the skin care composition (cream) prepared according to example 2 of the present application in an eye wrinkle test in volunteers;
FIG. 3 is a graph showing the change in facial red blood streak before and after 28 days of use of the skin care composition (cream) prepared in example 2 of the present application in the hemoglobin content test.
Detailed Description
The technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are only a part of the embodiments of the present application, and not all of the embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the description herein are intended to be within the scope of the present disclosure.
In a first aspect, the present application provides a skin care composition, wherein the skin care composition comprises, based on the total weight of the skin care composition: 1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 0.1-8wt% of peptide, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of sea fennel extract, 0.1-8wt% of tulip flower extract and 0.1-8wt% of mussel extract, and the balance of water.
In the skin care composition described herein, the content of vitreous origin is 1-15wt%. The content of the vitreous humor may be 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, or any two of the above-described values as endpoints. Boseine, also known as hydroxypropyl tetrahydropyrane triol (C) 8 H 16 O 5 ) Xylose derivatives extracted from beech, which stimulate the production of skin aminodextran (GAGs), promote the synthesis of GAGs and proteoglycans, improve the ultrastructure of dermal junction (DEJ), maintain the elasticity of dermis, promote the synthesis of collagen, constitute extracellular matrix, promote the combination of proteoglycans with elastin, collagen, etc., constitute a lattice structure, increase the firmness of cells and skin, enhance the elasticity of skin, repair damaged skin, and delay skin aging. The source of the vitreous color factor is not particularly limited in the present application as long as the object of the present invention can be achieved, and for example, vitreous color factor prepared by zhuiaibai pharmaceutical company is used as a component in a skin care composition.
The skin care compositions described herein contain 1-5wt% glycerol glucoside. The glycerol glucoside may be present in an amount of 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, or any two of the above-described values as endpoints. Glycerol glucoside (C) 9 H 18 O 8 ) Can activate aging cells, increase vitality and metabolic activity of weak cells, activate type I collagen precursor in aging cells, enhance skin elasticity, promote wound healing, and repair skin. The source of the glycerol glucoside in the present application is not particularly limited as long as the object of the present invention can be achieved, and for example, torreya nucifera is usedGlycerol glucosides prepared by pharmaceutical companies are used as components in skin care compositions.
The skin care composition described herein has a soluble collagen content of 0.1-5wt%. The soluble collagen content can be 0.1wt%, 0.3wt%, 0.5wt%, 0.7wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, or any two of the foregoing as endpoints. Soluble collagen, which is widely distributed in human tissues, is an important protein constituting the human body and accounts for more than 30% of the total protein content of the human body; the collagen is divided into 28 types according to different amino acid sequences, wherein the content of type I collagen accounts for about 80 percent of the total amount of the collagen, and the sum of the type I collagen, the type II collagen and the type III collagen accounts for more than 90 percent of the total amount of the collagen. The soluble collagen is mainly used for maintaining the shape and structure of skin and tissues and organs, and is also an important raw material for repairing each damaged tissue. The application preferably adopts the collagen (INCI name: soluble collagen) which belongs to type I collagen, has a structure similar to that of human skin, has small molecular weight, and is easy to permeate the skin epidermis and be really absorbed; it can achieve anti-aging effect by promoting cell activity and polarity, and can repair skin stratum corneum, promote repair of human keratinocyte, promote skin barrier promotion, repair skin erythema, and promote hyaluronic acid regeneration. The source of the soluble collagen in the present application is not particularly limited as long as the object of the present invention can be achieved, and for example, soluble collagen (BeriCos) prepared by sekurui pharmaceutical company is used TM Collagen-like skin Collagen) as a component in a skin care composition.
The skin care compositions described herein contain beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine in an amount of 0.1 to 8% by weight. The amount of beta-alanyl hydroxyproline diaminobutyric acid benzylamine may be 0.1wt%, 0.3wt%, 0.5wt%, 0.7wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt% or any two of the above-mentioned values as endpoints. Beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, a novel small molecule snake venom peptide, which prevents the combination of acetylcholine with a receptor by binding to a muscle-type nicotinic acetylcholine receptor, and finally leads to receptor blocking; in the closed state, sodium ions are not released and the muscle is therefore relaxed, which is more effective in reducing wrinkles caused by expression muscle contractions than other types of snake venom peptides. The beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine also has the effect of botulinum toxin, immediately and powerfully fades expression lines, can safely and effectively solve eye lines, headup lines, statutory lines and the like, and is a safer, milder and effective substitute for botulinum toxin. The source of the soluble collagen is not particularly limited in the present application as long as the object of the present invention can be achieved, and for example, β -alanyl hydroxyproline diaminobutyric acid benzylamine (Erasin 0003) manufactured by shenzhen zhenzhen villa pharmaceutical research and development limited is used as a component of a skin care composition.
The skin care composition described herein has a peptide content of 0.1-8wt%. The amount of peptides may be 0.1wt%, 0.3wt%, 0.5wt%, 0.7wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, or any two of the above-described values as endpoints.
The skin care composition described herein has an inositol content of 0.1-3wt%. The content of inositol may be 0.1wt%, 0.3wt%, 0.5wt%, 0.7wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, or any two of the above-described values as endpoints. Inositol, also known as inositol (C) 6 H 12 O 6 ) The natural penetration factor is excellent and can promote the active substances to penetrate into the dermis through the epidermis of the skin; the skin moisturizing cream can also promote hydration, reduce the moisture loss of the epidermis through the hydration, and promote the activity of the skin surface enzyme, thereby achieving the purposes of improving the skin feel, moisturizing the skin, tendering the skin, improving the skin moisture, and improving the skin surface, micro-wrinkles and textures; inositol can also form a barrier to restore lipid barrier integrity, to protect, nourish, defend the skin, moisturize, and improve skin feel. Inositol can reduce collagen decomposition or elastic tissue deformation (matrix metalloproteinase antibody), enhance fibroblast transmission, achieve anti-saccharification, DNA repair, anti-inflammation and anti-oxidation effects, and finally achieve the effects of enhancing skin elasticity and softness, reducing skin wrinkles,the effect of reducing the signs of aging is evident. The source of inositol is not particularly limited as long as the object of the invention can be achieved, and for example, inositol prepared by dupont is used as a component in a skin care composition.
The skin care composition described herein has a ceramide content of 0.1 to 5wt%. The ceramide may be present in an amount of 0.1wt%, 0.3wt%, 0.5wt%, 0.7wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, or any two of the foregoing as endpoints.
The ergothioneine content of the skin care compositions described herein is from 0.01 to 1wt%. The ergothioneine content may be 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, or any two of the above-described values as endpoints. Ergothioneine (C) 9 H 15 N 3 O 2 S) is a natural amino acid, has the capacity of resisting oxidation and removing free radicals, can resist the damage of ultraviolet rays to skin cells, excites the natural antioxidant defense system of the cells, reduces the formation of active oxygen, protects the cells from radiation damage, relieves skin inflammation and light damage caused by the ultraviolet rays, inhibits the activity of melanocytes, reduces the generation of melanin, brightens skin color, improves light aging, and has the functions of resisting aging, diminishing inflammation and repairing. The source of ergothioneine is not particularly limited as long as the object of the invention can be achieved, and for example, ergothioneine prepared by Huaxi biosciences is used as a component in a skin care composition.
In the skin care composition, the content of the hypecoum vulgare extract is 0.01-1wt%. The content of the hypecoum vulgare extract may be 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, or any two of the above-mentioned values as endpoints. Craib EXTRACT (catalog of names of used cosmetic raw materials (2021 edition) No. 02724, INCI name: CRITMUM MARITIUM EXTRACT; chinese name: craib EXTRACT; CAS No. 89997-98-8) is an EXTRACT of a plant of Salicornia Bigelivii (found in coastal areas of rock, not submerged by sea tide due to growing in high-altitude areas, growing on the coast line or upper island of the English gorge, atlantic and Mediterranean sea and coastal areas of the Canari island, coast of the Black sea area), which can significantly reduce the loss of skin moisture and lock skin moisture by promoting skin hydration, has a better moisturizing effect and reduces the generation of skin fines; in addition, the hypecoum extract is rich in aromatic molecules, and has anti-inflammatory and soothing effects by inhibiting inflammatory cytokines and regulating neuropeptides. The source of the anise extract is not particularly limited as long as the object of the invention can be achieved, and, for example, anise extract (natural ESSENCE) prepared by the company sibira is used as a component of the skin care composition.
In the skin care composition, the content of tulip flower extract is 0.1-8wt%. The tulip flower extract can be present in an amount of 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, or any two of the foregoing as endpoints. The tulip FLOWER EXTRACT (serial number of 08240 in the index of names of used cosmetic raw materials (2021 edition)) is rich in specific flavonoid compounds with strong oxidation resistance, has the characteristics of high antioxidant and skin barrier enhancement, can effectively resist oxidation stress, reduce the damage and erosion of exposure factors (light radiation, environmental pollutants, life style and the like), increase the thickness of epidermis, improve the barrier function, promote the hydration of skin, increase the content of ceramide, promote the synthesis of fibrillin, elastin and vimentin, maintain the integrity of a dermis layer structure, activate the expression and synthesis of hyaluronic acid, activate/rebuild active skin components, comprehensively rebuild the epidermis barrier and the dermis layer structure, protect the skin and resist aging. The source of tulip flower extract is not particularly limited in this application as long as the object of the invention can be achieved, for example, dumaflorine type tulip flower extract manufactured by Green Pharma company is used as a component of the skin care composition.
The skin care composition described herein comprises mussel extract in an amount of 0.1-8wt%. The mussel extract may be present in an amount of 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, or any two of the foregoing as endpoints. MUSSEL EXTRACT (serial numbers of 07672, INCI name: MUSSEL EXTRACT; chinese name: MUSSEL EXTRACT; CAS number: 94465-78-8 in the catalogue of names of used cosmetic raw materials (2021 edition)) can form a protective film on the surface of skin, and provide a good skin environment for barrier repair; has excellent anti-inflammatory effect, and can rapidly relieve allergy, reduce redness, and improve discomfort such as stabbing pain and burning sensation. The source of the mussel extract is not particularly limited as long as the object of the invention can be achieved, and for example, mussel extract (manufactured by USUNBIO corporation) is used100 As a component in a skin care composition.
In some embodiments of the present application, the peptide is selected from at least one of acetyl hexapeptide-8, snake venom peptide, L-arginine/L-lysine polypeptide, and carnosine, preferably from L-arginine/L-lysine polypeptide. The L-arginine/L-lysine polypeptide (CAS number: 31014-78-5) is composed of 22 amino acids, has highly folded structure, strong penetrating power, strong muscle contraction inhibition effect and quick and instant wrinkle removing effect; the L-arginine/L-lysine polypeptide has definite target spots, can target various voltage sensitive muscle sodium ion channels, block the channel Nav1.4, and can keep the nerve muscle current conduction of a small part of muscles, so that the expression muscles can be effectively relaxed, wrinkles can be effectively removed immediately, the skin is tightened, the skin wrinkle depth and roughness can be effectively reduced in a short time, and the skin condition is improved. The source of the L-arginine/L-lysine polypeptide is not particularly limited in the present applicationAs long as the object of the present invention can be achieved, for example, L-arginine/L-lysine polypeptide (produced by Shenzhen Vickers Co.) (AWSmooth) as a component in skin care compositions.
In some embodiments of the present application, the ceramide is selected from at least one of ceramide EOP, ceramide NP, ceramide AS, and ceramide AP, preferably from ceramide NP. Ceramide NP (C) 36 H 71 NO 4 ) Is the main component of physiological intercellular lipid in skin, has the same structure as human skin, can enhance the natural barrier function of skin, increase the water content of skin, recover the elasticity of skin and resist aging, and has better repairing effect on sensitive skin and atopic dermatitis. The source of the ceramide NP in the present application is not particularly limited as long as the object of the present invention can be achieved, and for example, ceramide NP prepared by duoshan corporation in korea is used as a component in a skin care composition.
In some embodiments of the present application, the skin care composition comprises, based on the total weight of the skin care composition: 10wt% of vitronectin, 2wt% of glycerol glucoside, 3wt% of soluble collagen, 5wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 2wt% of L-arginine/L-lysine polypeptide, 1wt% of inositol, 2wt% of ceramide NP, 0.2wt% of ergothioneine, 0.1wt% of sea fennel extract, 5wt% of tulip flower extract and 3wt% of mussel extract, and the balance of water.
In some embodiments of the present application, the skin care composition further comprises at least one of cetearyl olivate/sorbitan olivate, cetearyl alcohol, beeswax, isononyl isononanoate, shea butter, dimethicone, tocopherol palmitate, sodium hyaluronate, glycerol, butylene glycol, disodium EDTA, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, p-hydroxyacetophenone, 1, 2-hexanediol, and a fragrance.
The essence employed in the present application is preferably a (daily use) essence; the CAS number of Sodium Hyaluronate (Sodium Hyaluronate) described herein is 9067-32-7; the CAS number for the HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER (HYDROXYETHYL ACRYLATE/SODIUM ACRYLOYLDIMETHYL TAURATE COPOLYMER) described herein is 111286-86-3; the SHEA BUTTER fruit resin (INCI name: BUTYROSPERMUM PARKII (SHEA BUTTER)) described in this application has the sequence number in the book of used cosmetic raw materials (2021 edition): 04891.
in some embodiments of the present application, the skin care composition comprises, based on the total weight of the skin care composition: 1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxyprolinyl diaminobutyric acid benzylamine, 0.1-8wt% of peptides, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of hypsizygus marmoreus extract, 0.1-8wt% of tulip extract, 0.1-8wt% of mussel extract, 1-5wt% of cetearyl olive oleate/sorbitan olive oleate, 0.1-5wt% of cetearyl alcohol, 0.1-4wt% of beeswax, 2-10wt% of isononyl isononanoate, 0.5-5wt% of shea butter, 0.1-5wt% of polydimethylsiloxane, 0.1-3wt% of tocopherol palmitate, 0.01-0.3wt% of sodium hyaluronate, 2-15wt% of glycerol, 2-10wt% of butanediol EDTA, 0.01-0.3wt% of disodium edetate, 0.1-5wt% of hydroxyethyl acrylate, 0.1-0.1 wt% of dimethyl ethyl acrylate, 0.05-0.1-1 wt% of sodium-4 wt% of methyl-4 wt%, and the balance of sodium-2-4% of sodium-2% of methyl-4% of hydroxyethyl hexanoyl hexanoate.
In some embodiments of the present application, the skin care composition comprises, based on the total weight of the skin care composition: 10wt% of vitronectin, 2wt% of glycerol glucoside, 3wt% of soluble collagen, 5wt% of beta-alanyl hydroxyproline diaminobutyric acid benzylamine, 2wt% of L-arginine/L-lysine polypeptide, 1wt% of inositol, 2wt% of ceramide NP, 0.2wt% of ergothioneine, 0.1wt% of hypsizygus marmoreus extract, 5wt% of tulip flower extract, 3wt% of mussel extract, 2wt% of cetearyl olive oleate/sorbitan olive oleate, 1wt% of cetearyl alcohol, 0.5wt% of beeswax, 4wt% of isononyl isononanoate, 1wt% of shea butter, 2wt% of polydimethylsiloxane, 0.5wt% of tocopherol palmitate, 0.05wt% of sodium hyaluronate, 3wt% of glycerol, 3wt% of butanediol, 0.05wt% of disodium EDTA, 0.2wt% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 0.5wt% of p-hydroxy-acetophenone, 0.5wt% of 1, 2-hexanediol, and 0.05wt% of sperm, the balance being water.
The present application is not particularly limited as long as the object of the present invention can be achieved, for example, the method for preparing the skin care composition described above includes: mixing the components, and stirring to obtain skin care composition; or accurately weighing each component of the skin care product composition at normal temperature, stirring and dissolving the solid component completely by using the liquid component, adding the vitreous color for stirring dilution or dissolving and mixing uniformly, adding the soluble collagen, adding the rest water, and stirring uniformly to obtain the skin care product composition; or comprises the following steps: s1: adding cetearyl olivate/sorbitan olivate, cetearyl alcohol, beeswax, isononyl isononanoate, shea butter, polydimethylsiloxane and tocopherol palmitate into an oil pan, stirring for 10-20 min, and heating to 80-85 deg.C to obtain oil phase material A phase; s2: adding water, sodium hyaluronate, glycerol, butanediol, p-hydroxyacetophenone, EDTA disodium and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer into a water phase pot, stirring for 10-20 minutes, and heating to 80-85 ℃ to obtain a water phase material B phase; s3: pumping the oil phase material A phase obtained in the step S1 into an emulsifying pot through a filtering device; s4: pumping the water phase material B phase obtained in the step S2 into the emulsifying pot containing the oil phase material A in the step S3 through a filtering device, stirring at a high speed, homogenizing at the speed of 3000-3500 rpm for 10-20 minutes after uniformly stirring, and obtaining a mixed material C phase; s5: stirring and cooling the material C phase obtained in the step S4, vacuumizing, and stirring and cooling to 45 ℃; s6: cooling the material obtained in the step S5 to 40-45 ℃, adding the boscalid, the glycerol glucoside, the soluble collagen, the beta-alanyl hydroxy prolyl amino butyryl benzylamide, the peptides, the inositol, the ceramide, the ergothioneine, the hypecol extract, the tulip flower extract and the mussel extract, stirring for 10-20 minutes, and homogenizing for 3-5 minutes until the mixture is uniformly mixed; s7: continuously stirring and cooling to 35-38 deg.C, filtering, discharging, aging, and inspecting to obtain skin care composition (cream).
Hereinafter, embodiments of the present application will be described in more detail with reference to examples and comparative examples. Various tests and evaluations were carried out according to the following methods. Unless otherwise specified, "part" and "%" are based on mass. The components used are commercially available unless otherwise specified.
The following examples and comparative examples use a soluble collagen as the belicos from the pharmaceutical company beret seiki TM Collagen of Collagen type Collagen; beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine is Erasin0003 purchased from Shenzhen Weiqi medicine research and development Limited; the Crispum vulgare extract is NATIVE ESSENCE available from Saybox; tulip flower extract was purchased from Dumaflorine of Green Pharma; the mussel extract is obtained from USUNBIO100, respectively; cetearyl Olive oleate/sorbitan Olive oleate are Olive 1000 available from Haoster; the Shea butter is a Lipex Shea purchased from AAK company; the polydimethylsiloxane was PMX 200Fluid 100cst available from Dow Corning; sodium Hyaluronate was Sodium Hyaluronate available from forrestat; hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer is SEPINOV EMT 10 available from Sebick.
Example 1
A skin care composition comprising, based on the total weight of the skin care composition: 10wt% of vitronectin, 2wt% of glycerol glucoside, 3wt% of soluble collagen, 5wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 2wt% of L-arginine/L-lysine polypeptide, 1wt% of inositol, 2wt% of ceramide NP, 0.2wt% of ergothioneine, 0.1wt% of sea fennel extract, 5wt% of tulip flower extract and 3wt% of mussel extract, and the balance of deionized water.
The preparation method of the skin care composition comprises the following steps: mixing the above components, and stirring to obtain skin care composition.
Example 2
A skin care composition comprising, based on the total weight of the skin care composition: 10wt% of vitronectin, 2wt% of glycerol glucoside, 3wt% of soluble collagen, 5wt% of beta-alanyl hydroxyprolinyl diaminobutyric acid benzylamine, 2wt% of L-arginine/L-lysine polypeptide, 1wt% of inositol, 2wt% of ceramide NP, 0.2wt% of ergothioneine, 0.1wt% of hypecol extract, 5wt% of tulip flower extract, 3wt% of mussel extract, 2wt% of cetearyl olivate/sorbitan olivate, 1wt% of cetearyl alcohol, 0.5wt% of beeswax, 4wt% of isononyl isononanoate, 1wt% of shea butter, 2wt% of polydimethylsiloxane, 0.5wt% of tocopherol palmitate, 0.05wt% of sodium hyaluronate, 3wt% of glycerol, 3wt% of butylene glycol, 0.05wt% of disodium EDTA, 0.2wt% of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 0.5wt% of sodium p-hydroxybenzyl sulfonate, 0.5wt% of 1, 2-hexanediol, and (balance) 0.05wt% of essence, the balance daily use of deionized water.
The preparation method of the skin care composition comprises the following steps:
s1: adding cetearyl olive oleate/sorbitan olive oleate, cetearyl alcohol, beeswax, isononyl isononanoate, shea butter, polydimethylsiloxane and tocopherol palmitate into an oil pan, stirring for 10-20 minutes, and heating to 80-85 ℃ to obtain an oil phase material A phase;
s2: adding deionized water, sodium hyaluronate, glycerol, butanediol, p-hydroxyacetophenone, EDTA disodium and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer into a water phase pot, stirring for 10-20 minutes, and heating to 80-85 ℃ to obtain a water phase material B phase;
s3: pumping the oil phase material A phase obtained in the step S1 into an emulsifying pot through a filtering device;
s4: pumping the water phase material B phase obtained in the step S2 into the emulsifying pot containing the oil phase material A in the step S3 through a filtering device, stirring at a high speed, homogenizing at the speed of 3000-3500 rpm for 10-20 minutes after uniformly stirring, and obtaining a mixed material C phase;
s5: stirring and cooling the material C phase obtained in the step S4, vacuumizing, and stirring and cooling to 45 ℃;
s6: cooling the material obtained in the step S5 to 40-45 ℃, adding the boscalid, the glycerol glucoside, the soluble collagen, the beta-alanyl hydroxy prolyl amino butyryl benzylamide, the peptides, the inositol, the ceramide, the ergothioneine, the hypecol extract, the tulip flower extract and the mussel extract, stirring for 10-20 minutes, and homogenizing for 3-5 minutes until the mixture is uniformly mixed;
s7: continuously stirring and cooling to 35-38 deg.C, filtering, discharging, aging, and inspecting to obtain skin care composition (cream).
Examples 3 to 5
The procedure of example 2 was repeated, except that the compounding ratio of each component was adjusted as shown in Table 1.
Comparative examples 1 to 8
The procedure of example 2 was repeated, except that the kinds and ratios of the components were adjusted as shown in Table 1, and that the components not added were omitted in step S6.
The kinds and the proportions of the components of examples 1 to 5 and comparative examples 1 to 8 are shown in Table 1 below.
Performance and efficacy testing
1. Zebrafish repair efficacy test
Zebrafish are capable of completely regenerating most damaged tissues and are widely used to reveal mechanisms of vertebrate embryonic development and regeneration. Mechanical injury to the tail fin of zebra fish will result in damage to the skin and cartilage tissue, and observation of the rate of tail fin regeneration can be used to assess the efficacy of the test subject in promoting tissue regeneration. According to the method, a zebra fish tail fin damage repairing model is adopted, mechanical damage is carried out on tail fins, and then the repairing efficacy of the sample to be tested is evaluated by comparing the regeneration degrees of the tail fins of a blank group and a test group.
(1) Test samples: test animal samples: the experimental animal, wild type AB strain zebra fish, selects adult/sub-adult zebra fish with body length more than 3.5cm and body weight more than 0.5 g, the body length and body weight are basically equivalent, and a part of tail fin is cut out by operation to make a model. Skin care product composition sample to be tested: example 1 the resulting skin care composition was prepared.
(2) Testing an instrument: (1) a zebra fish farming system purchased from Shanghai Sheng biological laboratory Equipment, inc.; (2) research grade stereomicroscope, available from Nikon corporation; (3) balance, minimum weight 0.01g, available from Shanghai Yingweigh electronic Scale, inc.
(3) A culture environment: keeping the water temperature at 28 +/-1 ℃; the daily illumination time is 8-10 hours; change water 1 time every 2 days.
(4) The test method comprises the following steps: 1) Dividing zebra fish into 2 groups, wherein the 1 st group is a blank control group, the 2 nd group is a test group, and each group comprises 20 zebra fish;
2) Respectively cutting off the fish tail of the zebra fish in the blank group and the test group by using sterilized surgical scissors, and respectively returning the cut zebra fish to the original tank, wherein 0.1g of feed is fed into each group per day according to the requirement;
3) After each water change and feeding, 0.2wt% of the skin care composition prepared in example 1 was added to the test group 2, and on days 0, 3, 7, and 14, the zebrafish of groups 1 and 2 were individually placed under a microscope to observe and measure the area of tail fin regeneration, and the average value was taken to observe the condition of tail repair.
(5) And (3) testing results: the tail fin regeneration area for each group is shown in table 2.
TABLE 2 regeneration area (mm) of tail fins for each group 2 )
Test sample | 3 days | 7 days | 14 days | Significance of |
Blank control group | 5.53±0.67 | 9.29±1.84 | 15.95±1.89 | / |
Test set (example 1) | 7.58±0.56 | 11.83±1.91 | 21.64±3.56 | *** |
Note: ". Indicates a significance of 99%
As can be seen from the results in table 2, the ratio of the components in the skin care composition according to example 1 is controlled within the range of the present application, and the fishtail repair rate of the test group added with the skin care composition prepared in example 1 is significantly faster than that of the blank control group. Comparative graph of change after the white control group and the test group repaired the fish tail for 14 days in the zebra fish repair efficacy test is shown in fig. 1, and it can be seen from fig. 1 that the fish tail repair rate of the test group added with the skin care composition prepared in example 1 is significantly faster than that of the blank control group. The above results show that the skin care composition prepared in example 1 has a remarkable repairing effect on injured tissues.
2. Antioxidant Properties-measurement of the scavenging ratio of DPPH (1, 1-diphenyl-2-trinitrophenylhydrazine) free radical
Multiple electron-withdrawing-NO due to DPPH molecules 2 And a pi bond of a benzene ring, thereby having a nitrogen radical stably present, and when DPPH radical is eliminated, the absorbance A at the maximum absorption wavelength of 517nm is reducedAnd thus the clearance of its free radicals can be detected. Since the accumulation of DPPH radicals is an important factor in causing aging in human body, the clearance rate of DPPH radicals may reflect the anti-aging ability of the test sample.
(1) The test method comprises the following steps:
preparing a sample to be tested: 20mg of the skin care product composition samples prepared in the examples 2-5 and the comparative examples 1-8 are taken respectively, dissolved by absolute ethyl alcohol and subjected to constant volume to 250mL, and 12 samples to be detected are obtained.
Preparation of DPPH solution: 20mg of DPPH is weighed, dissolved by absolute ethyl alcohol and is metered to 250mL, and DPPH solution is obtained.
Ai group (sample test group): 2mL of each of the 12 samples were added to a different tube, and 2mL of the DPPH solution was added to each tube.
Ac group (solvent blank control group): 2mL of absolute ethanol and 2mL of the above DPPH solution were added to the tube.
Aj group (blank group): 2mL of each of the 12 samples to be tested are taken, added into different test tubes respectively, and 2mL of absolute ethyl alcohol is added into the test tubes.
And plugging the test tubes, standing for 30 minutes in a dark place at room temperature, measuring the absorbance of each group at the wavelength of 517nm by adopting a spectrophotometry, performing 5 parallel tests on each group of samples, and calculating the average value of the samples.
The DPPH radical clearance is calculated according to the following formula:
clearance (%) = [1- (Ai-Aj)/Ac ] × 100%;
where Ai, ac, and Aj represent absorbances of Ai group, ac group, and Aj group, respectively.
The greater the DPPH clearance rate, the stronger the ability of the skin care composition to scavenge free radicals and resist oxidation.
(2) And (3) testing results: the DPPH radical scavenging results obtained for each skin care composition are shown in table 3.
TABLE 3 DPPH radical scavenging results (%)
As shown in Table 3, the skin care compositions of examples 2-5, in which the ratios of the components were controlled within the ranges of the present application, showed high DPPH radical scavenging rates, indicating good antioxidant properties.
The inventors unexpectedly found that the inositol content in the skin care composition according to example 4 was increased to 3wt%, the tulip flower extract content in the skin care composition according to example 5 was increased to 8wt%, and the skin care compositions according to examples 4 and 5 had higher DPPH radical scavenging rate and better oxidation resistance, indicating that the inositol and tulip flower extracts have better oxidation resistance; moreover, the skin care composition corresponding to example 2 has the highest DPPH free radical scavenging rate, which indicates that the ergothioneine, inositol and tulip flower extract are compounded in a specific ratio, and the components act synergistically, so that the skin care composition has a higher DPPH free radical scavenging rate and better antioxidant and anti-aging effects.
In contrast, comparative examples 7 and 8, which correspond to skin care compositions without ergothioneine, have low DPPH radical scavenging rate, indicating that ergothioneine plays an important role in scavenging DPPH radicals.
3. Human body efficacy testing
The tester: 120 female volunteers aged 38-55 years old were selected, the selected volunteers had dry, dark, yellow skin, obvious wrinkles on the face and eyes, and were randomly and equally divided into 12 groups of 10 subjects, each subject was informed of the entire study and signed with informed consent.
Test samples: examples 2-5 and comparative examples 1-8 samples of the skin care compositions prepared.
The test method comprises the following steps: after each test person cleaned the face once a day, morning and evening, each person of each group used a cream sample for every 10 persons, and the skin care composition samples prepared according to examples 2-5 and comparative examples 1-8 were applied evenly to the face in that order, without using other cosmetics for the test period, for 4 weeks. The moisture content of facial skin, the skin water loss (TEWL value), the skin elasticity (ISE value), the eye wrinkles, the hemoglobin content, etc. before and after use were measured by tracking, and the average value was taken every 2 weeks.
All test persons had a 30 minute rest in the test environment after cleansing the face on days 0, 14, 28, after which the test was performed, wherein: (1) Measuring the water content of the facial skin by adopting a skin stratum corneum water content tester MoistrureMeterSC (Delfin, finland), and reading a display value of an instrument; (2) The percutaneous water loss (TEWL value) was measured using a skin water loss tester VapoMeter (Delfin, finland), and the instrument display was read; (3) Skin elasticity (ISE value) an elastometer (Delfin, finland) was used, and the reading instrument indicated a value; (4) Eye wrinkles were measured using a skin imaging meter, andrera 3D (artera, ireland), and the meter display values were read; selecting the positions of the face and the canthus of the tested person, calculating the volume and the area of all wrinkles of the sampling part, averaging the data of all tested persons and calculating the wrinkle reduction rate; (5) The hemoglobin content was measured using a skin imaging meter, andrera 3D (andrera, ireland), and the meter was read to show the value.
Testing environment requirements: the temperature is 21 +/-1 ℃; relative humidity of 50 + -5% RH; the illumination condition is as follows: the color temperature is 5500-6500K.
And (3) testing results:
(1) Facial skin moisture test
The results of the facial skin moisture test are shown in table 4. Wherein the change after 28 days (%) = (water content of facial skin at 28 days-water content of facial skin at 0 days)/water content of facial skin at 0 days x 100%.
Table 4 facial skin moisture test results for each skin care composition
Test sample | Day 0 | 14 days | 28 days | Change value after 28 days (%) |
Example 2 | 42.3 | 47.7 | 53.6 | 26.7 |
Example 3 | 35.9 | 41.3 | 45.1 | 25.63 |
Example 4 | 38.6 | 42.5 | 48.7 | 26.2 |
Example 5 | 34.7 | 38.8 | 43.3 | 24.8 |
Comparative example 1 | 37.5 | 40.5 | 42.9 | 14.4 |
Comparative example 2 | 33.1 | 35.8 | 38.2 | 15.4 |
Comparative example 3 | 37.2 | 39.3 | 41.7 | 12.1 |
Comparative example 4 | 41.2 | 43.5 | 46.8 | 13.6 |
Comparative example 5 | 35.7 | 37.4 | 41.8 | 17.1 |
Comparative example 6 | 36.8 | 40.1 | 42.1 | 14.4 |
Comparative example 7 | 33.9 | 35.4 | 38.2 | 12.7 |
Comparative example 8 | 37.5 | 38.7 | 40.1 | 6.9 |
(2) Percutaneous Water loss (TEWL value) test
The results of the percutaneous water loss (TEWL values) test are shown in Table 5. Wherein, change value after 28 days (%) = (TEWL value at 28 days-TEWL value at 0 days)/TEWL value at 0 days × 100%.
TABLE 5 test results for skin care compositions for trans-dermal water loss (TEWL value)
(3) Skin elasticity (ISE value) test
The results of the skin elasticity (ISE value) test are shown in table 6. Wherein change after 28 days (%) = (ISE value at 28 days-ISE value at 0 days)/ISE value at 0 days × 100%.
Table 6 skin elasticity (ISE value) test results for each skin care composition
Test sample | Day 0 | 14 days | 28 days | Change value after 28 days (%) |
Example 2 | 45.2 | 51.7 | 58.9 | 30.3 |
Example 3 | 46.3 | 52.4 | 59.6 | 28.7 |
Example 4 | 41.9 | 47.3 | 53.5 | 27.7 |
Example 5 | 48.7 | 55.6 | 62.9 | 29.2 |
Comparative example 1 | 49.1 | 53.8 | 56.2 | 14.5 |
Comparative example 2 | 45.9 | 49.2 | 53.1 | 15.7 |
Comparative example 3 | 43.8 | 45.3 | 48.7 | 11.2 |
Comparative example 4 | 42.7 | 44.7 | 47.9 | 12.2 |
Comparative example 5 | 49.8 | 51.2 | 54.6 | 9.6 |
Comparative example 6 | 47.3 | 49.7 | 53.3 | 12.7 |
Comparative example 7 | 53.2 | 55.7 | 58.9 | 10.7 |
Comparative example 8 | 45.6 | 46.8 | 47.9 | 5.1 |
(4) Eye wrinkle testing
The eye wrinkle test results are shown in table 7. Wherein change (%) after 28 days is = (eye wrinkle value at 28 days-eye wrinkle value at 0 days)/eye wrinkle value at 0 days × 100%.
Table 7 eye wrinkle test results for each skin care composition
Test sample | Day 0 | 14 days | 28 days | Change after 28 days (%) |
Example 2 | 62.5 | 51.8 | 36.7 | -41.3 |
Example 3 | 58.3 | 45.6 | 34.7 | -40.5 |
Example 4 | 59.7 | 49.2 | 36.3 | -39.2 |
Example 5 | 61.9 | 51.7 | 37.2 | -39.9 |
Comparative example 1 | 55.3 | 45.7 | 42.5 | -23.15 |
Comparative example 2 | 51.7 | 43.9 | 37.8 | -26.7 |
Comparative example 3 | 46.5 | 41.3 | 37.9 | -18.5 |
Comparative example 4 | 50.3 | 46.1 | 42.3 | -15.9 |
Comparative example 5 | 48.9 | 44.5 | 40.3 | -17.6 |
Comparative example 6 | 60.3 | 52.8 | 47.5 | -21.2 |
Comparative example 7 | 57.4 | 45.3 | 43.3 | -24.6 |
Comparative example 8 | 58.1 | 55.6 | 52.7 | -9.3 |
(5) Heme content test
The results of the heme content test are shown in Table 8. Wherein the change after 28 days (%) = (heme content at 28 days-heme content at 0 days)/heme content at 0 days × 100%.
Table 8 results of the hemoglobin content test for each skin care composition
The comparison of the change of eye wrinkles of volunteers before using the skin care composition (cream) prepared in example 2 of the present application and after 28 days of use is shown in fig. 2; as can be seen from fig. 2, the number of eye wrinkles was significantly reduced before and after 28 days of the application of the skin care composition prepared in example 2 of the present application. The graph of the change of facial red blood streak before and after 28 days of use of the skin care composition (cream) prepared in example 2 of the present application in the heme content test is shown in fig. 3; as can be seen from FIG. 3, the number of facial red blood streaks was significantly reduced before and after 28 days of the application of the skin care composition prepared in example 2 of the present application. The results show that the skin care product composition prepared in the embodiment 2 has good wrinkle-removing, anti-aging, and (red-removing) repairing and relieving effects.
The higher the skin moisture content is, the better the skin moisturizing effect is; the higher the skin transdermal water loss (TEWL value), the weaker the skin barrier function; the higher the skin elasticity (ISE value) value, the better the skin elasticity is represented; the larger the value of the wrinkles of the eyes is, the better the wrinkle removing and anti-aging effects are; the larger the heme content value is, the better the (red-removing) soothing and repairing effect on the skin is.
From the results shown in tables 4 to 8, it can be seen that the skin care compositions of examples 2 to 5, in which the proportions of the components are controlled within the ranges of the present application, show better effects in various tests such as facial skin moisture content, skin transdermal moisture loss (TEWL value), skin elasticity (ISE value), eye wrinkles, hemoglobin content, etc.; the skin care composition corresponding to the example 2 achieves better effects in the five tests.
In contrast, the skin care composition corresponding to comparative example 1 had no vitronectin added thereto, and the skin care composition corresponding to comparative example 2 had no glycerol glucoside added thereto, so that the skin care compositions corresponding to comparative examples 1 and 2 had poor effects in all respects as compared with examples 2 to 5. Without being limited to any theory, the inventor of the application unexpectedly finds that the chromogen can promote the synthesis of collagen, increase the compactness of cells and skin, enhance the elasticity of the skin, repair damaged skin and delay skin aging; the glycerol glucoside can activate aged cells, enhance skin elasticity, promote wound healing, and repair skin. Therefore, as can be seen from example 2, comparative example 1 and comparative example 2, the absence of any ingredient in the formulation of the skin care composition affects the use of the final product.
The skin care composition corresponding to comparative example 3, which does not contain soluble collagen and inositol, has inferior moisture content of facial skin, skin elasticity and eye wrinkle test effects to those of example 2. Without being bound by any theory, the inventor of the application unexpectedly finds that the soluble collagen can promote cell activity, promote collagen generation, repair skin cuticle, promote skin barrier lifting and repair skin erythema; the inositol can promote hydration, reduce skin water loss, promote osmosis and promote the absorption of the skin to active substances, and the inositol and the skin water loss act synergistically to increase the absorption of the skin to the active substances, enhance the moisture retention of the skin, further enhance the skin elasticity and reduce wrinkles.
Comparative example 4 corresponds to a skin care composition without the addition of beta-alanyl hydroxy prolyl aminobutyrylbenzylamide, resulting in poorer skin elasticity and poorer eye wrinkle test results than examples 2-5. Without being bound by any theory, the inventors of the present application have unexpectedly found that beta-alanyl hydroxyprolimidobutyrylbenzylamide is more effective in reducing wrinkles caused by contraction of expression muscles, has botulinum toxin efficacy, strongly lightens expression lines in real time, and can safely and effectively solve eye lines, head-up lines, statutory lines, and the like.
Comparative example 5 corresponds to a skin care composition without adding L-arginine/L-lysine polypeptide and tulip flower extract, resulting in inferior skin elasticity and eye wrinkle test effects to example 2. Without being limited by any theory, the inventor of the application unexpectedly finds that the L-arginine/L-lysine polypeptide has a strong muscle contraction inhibiting effect, can immediately and effectively remove wrinkles and tighten the skin, can effectively reduce the depth and roughness of the skin wrinkles in a short time and improve the skin condition, and the tulip flower extract has the characteristics of high oxidation resistance, skin barrier enhancement, hydration promotion of collagen production, skin elasticity improvement and skin aging delay.
The skin care composition corresponding to comparative example 6, to which the ceramide NP and hypecoum extracts were not added, resulted in poorer results of skin water loss and heme content tests than example 2, i.e., greater water loss and poorer (red-removing) repair relief effect. Without being limited to any theory, the inventor of the application unexpectedly discovers that the ceramide NP can form a barrier protective film on the surface of the skin, can better prevent the skin moisture loss, has a certain repairing effect on the skin, and the hypecoum extract can obviously reduce the skin moisture loss, lock the skin moisture, enhance the moisturizing effect of the skin and reduce the generation of thin threads of the skin; the anisetree extract can also play a role in resisting inflammation and relieving through inhibiting inflammatory cytokines and regulating neuropeptides, more effectively reduce (reduce) the skin from being stimulated by the outside, resist inflammation and relieve and repair the skin, so that the water loss and the effect of relieving and repairing are adversely affected by the non-addition of the ceramide NP and the anisetree extract.
Comparative example 7 corresponds to a skin care composition without ergothioneine and mussel extract, resulting in less effective eye wrinkles and hemoglobin content tests than example 2. Without being limited to any theory, the inventor of the application finds that ergothioneine has a good antioxidant effect and effectively delays skin aging and wrinkles; the mussel extract has a good soothing and repairing effect, can provide a pleasant comfortable feeling for skin, can repair damaged skin, and can relieve external stimulation to the skin.
Comparative example 8 corresponds to a skin care composition without the addition of vitronectin, glycerol glucoside, soluble collagen, β -alanyl hydroxyproline diaminobutyric acid benzylamine, L-arginine/L-lysine polypeptide, inositol, ceramide NP, ergothioneine, hypecoum extract, tulip flower extract, and mussel extract, which showed poor effects in tests of facial skin moisture content, skin transdermal moisture loss (TEWL value), skin elasticity (ISE value), eye wrinkles, hemoglobin content, and the like.
Through analysis of the test results, the inventor of the application unexpectedly finds that the beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine and the L-arginine/L-lysine polypeptide have a synergistic effect under the synergistic effect, and can effectively reduce wrinkles, increase skin elasticity, improve fibroblast activity, enhance the anti-aging property of the skin and repair the skin. In addition, the inventor also unexpectedly finds that the combination of the vitriol, the glycerol glucoside and the inositol can better promote the skin hydration action, enhance the skin moisturizing effect, more effectively reduce (reduce) the skin from being stimulated by the outside, resist inflammation, relieve and repair the skin, and keep the skin elastic and glossy.
To sum up, the skin care product composition that this application provided is by the active of multiple different efficiency according to the certain proportion combination, each component synergism, all-round, many-sided performance efficiency effect, it is more obvious to make each side effect, can realize moisturizing, crease-resistant, anti-aging, the many efficiency of repair, increase skin moisturizing that can be better, can strengthen the barrier of skin elasticity and skin, the repair effect that the skin is releived is strengthened, repair injured skin, promote skin compactness, improve the skin roughness and ageing, effectively improve the instant anti-wrinkle effect of skin, instantaneous smoothness, reach anti-wrinkle anti-aging effect, make the skin reappear young.
The above description is only for the preferred embodiment of the present application and is not intended to limit the scope of the present application. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application are included in the protection scope of the present application.
Claims (10)
1. A skin care composition, wherein the skin care composition comprises, based on the total weight of the skin care composition:
1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxyproline diaminobutyric acid benzylamine, 0.1-8wt% of peptides, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of sea fennel extract, 0.1-8wt% of tulip flower extract, 0.1-8wt% of mussel extract and the balance of water.
2. The skin care composition of claim 1,
the peptide is selected from at least one of acetyl hexapeptide-8, snake venom peptide, L-arginine/L-lysine polypeptide and carnosine.
3. The skin care composition of claim 1,
the ceramide is selected from at least one of ceramide EOP, ceramide NP, ceramide AS and ceramide AP.
4. The skin care composition according to any one of claims 1 to 3,
the skin care composition further comprises at least one of cetearyl/sorbitan olivetoleate, cetearyl alcohol, beeswax, isononyl isononanoate, shea butter, dimethicone, tocopherol palmitate, sodium hyaluronate, glycerin, butylene glycol, disodium EDTA, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, p-hydroxyacetophenone, 1, 2-hexanediol, and a fragrance.
5. The skin care composition according to claim 4, wherein the skin care composition comprises, based on the total weight of the skin care composition:
1-15wt% of vitronectin, 1-5wt% of glycerol glucoside, 0.1-5wt% of soluble collagen, 0.1-8wt% of beta-alanyl hydroxy prolyl diaminobutyric acid benzylamine, 0.1-8wt% of peptides, 0.1-3wt% of inositol, 0.1-5wt% of ceramide, 0.01-1wt% of ergothioneine, 0.01-1wt% of hypsizygus marmoreus extract, 0.1-8wt% of tulip flower extract, 0.1-8wt% of mussel extract, 1-5wt% of cetearyl olive oleate/sorbitan olive oleate, 0.1-5wt% of cetearyl alcohol, 0.1-4wt% of beeswax, 2-10wt% of isononyl isononanoate, 0.5-5wt% of shea butter, 0.1-5wt% of polydimethylsiloxane, 0.1-3wt% of tocopherol palmitate, 0.01-0.3wt% of sodium hyaluronate, 2-15wt% of glycerol, 2-10wt% of butanediol disodium EDTA, 0.01-0.3wt% of hydroxyethyl acrylate, 0.1-5wt% of dimethyl ethyl acrylate, 0.05-1-5 wt% of sodium p-2, and the balance of sodium acryloyloxy-2, 4wt% of sodium acrylate copolymer.
6. Use of a skin care composition according to any one of claims 1 to 5 in the preparation of a skin care product.
7. The use according to claim 6, wherein the skin care product has moisturizing, anti-wrinkle, anti-aging, soothing, and repairing effects.
8. A skin care product comprising the skin care composition according to any one of claims 1 to 5.
9. The skin care product of claim 8, wherein the mass fraction of the skin care product composition is 5% -20%.
10. The skin care product according to claim 8 or 9, wherein the skin care product is one selected from a cream, a lotion, a serum, a moisturizing lotion, and a mask.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211003459.8A CN115400065B (en) | 2022-08-19 | 2022-08-19 | Skin care product composition with multiple effects of moisturizing, anti-wrinkle, anti-aging, relieving and repairing and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211003459.8A CN115400065B (en) | 2022-08-19 | 2022-08-19 | Skin care product composition with multiple effects of moisturizing, anti-wrinkle, anti-aging, relieving and repairing and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115400065A true CN115400065A (en) | 2022-11-29 |
CN115400065B CN115400065B (en) | 2024-08-09 |
Family
ID=84161963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211003459.8A Active CN115400065B (en) | 2022-08-19 | 2022-08-19 | Skin care product composition with multiple effects of moisturizing, anti-wrinkle, anti-aging, relieving and repairing and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115400065B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115721582A (en) * | 2022-11-30 | 2023-03-03 | 杭州泰禾四季化妆品有限公司 | Anti-aging essence containing exosomes and preparation method thereof |
CN117137822A (en) * | 2023-10-31 | 2023-12-01 | 杭州湃肽生化科技有限公司 | Anti-aging composition and application thereof |
CN118121504A (en) * | 2024-05-06 | 2024-06-04 | 深圳柏垠生物科技有限公司 | Mussel mucin-based composition, preparation method and application |
WO2024125471A1 (en) * | 2022-12-12 | 2024-06-20 | 南京纽邦生物科技有限公司 | Method and composition for improving or maintaining skin health of mammals |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934772A (en) * | 2019-12-25 | 2020-03-31 | 珠海贝美生物科技有限公司 | Wrinkle-removing and anti-aging composition and application thereof in cosmetics |
CN114224768A (en) * | 2021-12-13 | 2022-03-25 | 江苏江山聚源生物技术有限公司 | Repairing and anti-aging composition and preparation method thereof |
-
2022
- 2022-08-19 CN CN202211003459.8A patent/CN115400065B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934772A (en) * | 2019-12-25 | 2020-03-31 | 珠海贝美生物科技有限公司 | Wrinkle-removing and anti-aging composition and application thereof in cosmetics |
CN114224768A (en) * | 2021-12-13 | 2022-03-25 | 江苏江山聚源生物技术有限公司 | Repairing and anti-aging composition and preparation method thereof |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115721582A (en) * | 2022-11-30 | 2023-03-03 | 杭州泰禾四季化妆品有限公司 | Anti-aging essence containing exosomes and preparation method thereof |
WO2024125471A1 (en) * | 2022-12-12 | 2024-06-20 | 南京纽邦生物科技有限公司 | Method and composition for improving or maintaining skin health of mammals |
CN117137822A (en) * | 2023-10-31 | 2023-12-01 | 杭州湃肽生化科技有限公司 | Anti-aging composition and application thereof |
CN117137822B (en) * | 2023-10-31 | 2024-02-13 | 杭州湃肽生化科技有限公司 | Anti-aging composition and application thereof |
CN118121504A (en) * | 2024-05-06 | 2024-06-04 | 深圳柏垠生物科技有限公司 | Mussel mucin-based composition, preparation method and application |
CN118121504B (en) * | 2024-05-06 | 2024-08-16 | 深圳柏垠生物科技有限公司 | Mussel mucin-based composition, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN115400065B (en) | 2024-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115400065B (en) | Skin care product composition with multiple effects of moisturizing, anti-wrinkle, anti-aging, relieving and repairing and application thereof | |
CN112402310A (en) | Vitreous chromogen polypeptide anti-wrinkle eye cream and preparation method thereof | |
KR101796694B1 (en) | Cosmetic composition for improving skin whitening and lifting | |
CN111249209A (en) | Moisturizing repair cream and preparation method thereof | |
CN110731923A (en) | Enhanced moisturizing cosmetic compositions | |
CN111249215A (en) | Multi-effect whitening and freckle-removing cream and preparation method thereof | |
CN115154383B (en) | Mild whitening composition and whitening face cream thereof | |
CN109568203B (en) | Cosmetic composition with whitening and skin brightening effects | |
JP2008127313A (en) | Cosmetic and hair cosmetic obtained by blending egf (epidermal growth factor) | |
WO2024045952A1 (en) | Recombinant collagen-containing composition having effects of repairing and soothing, eye cream containing same, preparation method therefor, and use thereof | |
CN115040464A (en) | Essence composition with wrinkle-removing and anti-aging effects and preparation method thereof | |
CN113332227A (en) | Soothing and repairing composition and application thereof in cosmetics | |
CN113384507B (en) | Anti-aging composition and preparation method and application thereof | |
CN115517999B (en) | Anti-aging composition and application thereof in beauty and skin care | |
CN114224768A (en) | Repairing and anti-aging composition and preparation method thereof | |
CN113576975A (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
CN113018230A (en) | Composition and preparation method and application thereof | |
CN111803422A (en) | Oil control composition and application thereof | |
CN112587456A (en) | Repairing and whitening composition and preparation method thereof | |
CN117243844A (en) | Collagen-containing skin care product essence and preparation method and application thereof | |
AU2021369845A9 (en) | Retinol compositions, methods of their preparation and use | |
CN113368003A (en) | Composition with overnight muscle repairing effect and preparation method and application thereof | |
CN116139060B (en) | Composition with anti-inflammatory and anti-aging effects and preparation method and application thereof | |
CN112386627A (en) | Application of rosemary callus juice and culture medium for inducing rosemary callus | |
CN115869230A (en) | Anti-wrinkle cosmetic and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |